---
title: "Roivant Sciences (ROIV) Receives a Buy from Jefferies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296242233.md"
description: "Jefferies analyst maintained a Buy rating on Roivant Sciences today and set a price target of $42.00.Summer Sale - Claim 70% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks In addition to Jefferies, Roivant Sciences also received a Buy from J.P. Morgan’s Brian Cheng in a report issued on August 10. However, on August 7, Bank of America Securities reiterated a Hold rating on Roivant Sciences (NASDAQ: ROIV)."
datetime: "2026-08-18T14:05:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296242233.md)
  - [en](https://longbridge.com/en/news/296242233.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296242233.md)
generator: "portal-rs"
---

# Roivant Sciences (ROIV) Receives a Buy from Jefferies

Jefferies analyst maintained a Buy rating on Roivant Sciences today and set a price target of $42.00.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

In addition to Jefferies, Roivant Sciences also received a Buy from J.P. Morgan’s Brian Cheng in a report issued on August 10. However, on August 7, Bank of America Securities reiterated a Hold rating on Roivant Sciences (NASDAQ: ROIV).

### Related Stocks

- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Roivant Sciences (ROIV) Wins FDA Approval For LISRAYA, Is The Upside Already Priced In?](https://longbridge.com/en/news/298073390.md)
- [ROIV: Mosliciguat showed unprecedented efficacy and safety in PH-ILD, advancing to phase 3](https://longbridge.com/en/news/298312682.md)
- [Apalach Current Reaches 2,000 Subscribers as Independent Newsletter Expands Coverage of Florida’s Forgotten Coast](https://longbridge.com/en/news/298468032.md)
- [ROIV: PHocus trial data in PH-ILD and LISRAYA's launch highlight major advances and pipeline momentum](https://longbridge.com/en/news/298348190.md)
- [Public Relations Portal Introduces Subscription-Based Platform for Recurring Media Placements](https://longbridge.com/en/news/298200631.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**